(Q35967393)

11 August 2017

1 reference

title

New drugs for the treatment of attention-deficit/hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

11 August 2017

1 reference

1 reference

Caroly S Pataki

1

1 reference

11 August 2017

David T Feinberg

series ordinal

2

1 reference

11 August 2017

James J McGough

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Emerging Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

293-302

1 reference

Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Continuity of psychopathology in a community sample of adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Attention deficit/hyperactivity disorder across the lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD, and adult ADHD symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Pedigree disequilibrium test (PDT) replicates association and linkage between DRD4 and ADHD in multigenerational and extended pedigrees from a genetic isolate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A genomewide scan for loci involved in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Maternal smoking and hyperactivity in 8-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Hair lead levels related to children's classroom attention-deficit behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder: findings from the Ontario Child Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Attention-deficit/hyperactivity disorder treatment and later drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

21 January 2018

Stimulant medications

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Catecholamines in attention-deficit hyperactivity disorder: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Dopamine transporter density in patients with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Association of the dopamine transporter gene (DAT1) with poor methylphenidate response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.293

21 January 2018

Identifiers

DOI

10.1517/14728214.9.2.293

1 reference

11 August 2017

1 reference